These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38402253)

  • 1. Hippocampal volume changes after (R,S)-ketamine administration in patients with major depressive disorder and healthy volunteers.
    Evans JW; Graves MC; Nugent AC; Zarate CA
    Sci Rep; 2024 Feb; 14(1):4538. PubMed ID: 38402253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder.
    Niciu MJ; Iadarola ND; Banerjee D; Luckenbaugh DA; Park M; Lener M; Park L; Ionescu DF; Ballard ED; Brutsche NE; Akula N; McMahon FJ; Machado-Vieira R; Nugent AC; Zarate CA
    J Psychopharmacol; 2017 Dec; 31(12):1570-1577. PubMed ID: 29039254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals.
    Mkrtchian A; Evans JW; Kraus C; Yuan P; Kadriu B; Nugent AC; Roiser JP; Zarate CA
    Mol Psychiatry; 2021 Jul; 26(7):3292-3301. PubMed ID: 32929215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder.
    Lundin NB; Sepe-Forrest L; Gilbert JR; Carver FW; Furey ML; Zarate CA; Nugent AC
    J Affect Disord; 2021 Jan; 279():239-249. PubMed ID: 33074143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional changes in sleep-related arousal after ketamine administration in individuals with treatment-resistant depression.
    Ballard ED; Greenstein D; Reiss PT; Crainiceanu CM; Cui E; Duncan WC; Hejazi NS; Zarate CA
    Transl Psychiatry; 2024 Jun; 14(1):238. PubMed ID: 38834540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 7T
    Evans JW; Lally N; An L; Li N; Nugent AC; Banerjee D; Snider SL; Shen J; Roiser JP; Zarate CA
    Neuropsychopharmacology; 2018 Aug; 43(9):1908-1914. PubMed ID: 29748628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. κ-Opioid Receptor Plasma Levels Are Associated With Sex and Diagnosis of Major Depressive Disorder But Not Response to Ketamine.
    Quintanilla B; Medeiros GC; Greenstein D; Yuan P; Johnston JN; Park LT; Goes FS; Gould TD; Zarate CA
    J Clin Psychopharmacol; 2023 Mar-Apr 01; 43(2):89-96. PubMed ID: 36821406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hippocampal volume and the rapid antidepressant effect of ketamine.
    Abdallah CG; Salas R; Jackowski A; Baldwin P; Sato JR; Mathew SJ
    J Psychopharmacol; 2015 May; 29(5):591-5. PubMed ID: 25122038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.
    Moaddel R; Shardell M; Khadeer M; Lovett J; Kadriu B; Ravichandran S; Morris PJ; Yuan P; Thomas CJ; Gould TD; Ferrucci L; Zarate CA
    Psychopharmacology (Berl); 2018 Oct; 235(10):3017-3030. PubMed ID: 30116859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Volumetric changes in subcortical structures following repeated ketamine treatment in patients with major depressive disorder: a longitudinal analysis.
    Zhou YL; Wu FC; Liu WJ; Zheng W; Wang CY; Zhan YN; Lan XF; Ning YP
    Transl Psychiatry; 2020 Aug; 10(1):264. PubMed ID: 32747631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
    Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
    Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder.
    Abdallah CG; Jackowski A; Salas R; Gupta S; Sato JR; Mao X; Coplan JD; Shungu DC; Mathew SJ
    Neuropsychopharmacology; 2017 Jul; 42(8):1739-1746. PubMed ID: 28272497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
    Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
    J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder.
    Zhou YL; Wu FC; Wang CY; Zheng W; Lan XF; Deng XR; Ning YP
    J Affect Disord; 2020 Nov; 276():608-615. PubMed ID: 32871692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
    Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
    J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder.
    Murrough JW; Collins KA; Fields J; DeWilde KE; Phillips ML; Mathew SJ; Wong E; Tang CY; Charney DS; Iosifescu DV
    Transl Psychiatry; 2015 Feb; 5(2):e509. PubMed ID: 25689570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.
    Li CT; Chen MH; Lin WC; Hong CJ; Yang BH; Liu RS; Tu PC; Su TP
    Hum Brain Mapp; 2016 Mar; 37(3):1080-90. PubMed ID: 26821769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression.
    Acevedo-Diaz EE; Cavanaugh GW; Greenstein D; Kraus C; Kadriu B; Park L; Zarate CA
    J Psychiatr Res; 2020 Nov; 130():280-285. PubMed ID: 32861983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.